CervoMed已宣布,其药物Neflamapimod针对非流利变异型原发性进行性失语症(一种额颞叶痴呆)的第二阶段临床试验,现已成功完成患者入组工作。
CervoMed已宣布,其药物Neflamapimod针对非流利变异型原发性进行性失语症(一种额颞叶痴呆)的第二阶段临床试验,现已成功完成患者入组工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.